← Human Trials & Peer-Reviewed Studies
The exercise-induced increase in plasma levels of endothelin-1 is enhanced in patients with atherosclerotic coronary artery disease. Modulation by pentaerithrityltetranitrat (PETN)
Plain-language guide to PMID 7717184 (1995): placebo-controlled randomized controlled trial study of Endothelin-1 in 10 patients.
Key Facts
- PMID
- 7717184
- Journal
- Agents and actions. Supplements
- Year
- 1995
- Study type
- Randomized Controlled Trial
- Authors
- Predel HG et al. (6 authors)
- DOI
- 10.1007/978-3-0348-7346-8_32
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Endothelin-1.
The objective of the present study was to investigate a) the effects of ergometric exercise on ET-1 plasma concentrations in 10 patients with coronary artery disease (CAD) as compared to an age and sex matched control group and b) the modulatory role of the orally administered organic nitrate, pentaerithrityltetranitrat (PETN), in patients with CAD.
Who Took Part
The study group was 10 patients.
By PubMed's age tags, the people studied were middle-aged adults, men only.
10 male patients with CAD confirmed by coronarography and 10 male healthy controls underwent a bicycle ergometry according to the WHO-standards upt to 125 watts.
How the Study Was Run
In design terms this was a randomized, placebo-controlled and crossover study.
Random assignment meant chance, not the researchers, decided who got Endothelin-1 and who got the comparison, which limits bias.
Some patients received a placebo instead of Endothelin-1, giving a reference point.
Each person switched between Endothelin-1 and the comparison at some point, usually with a gap in between.
Venous blood samples for determination of ANP and ET-1 plasma concentrations were drawn in supine position directly before and 5 min after ergometric exercise.
What Was Measured
The subject headings attached to it are Analysis of Variance, Coronary Artery Disease, Endothelins, Exercise, Pentaerythritol Tetranitrate and Radioimmunoassay.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and crossover study of Endothelin-1 in 10 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1995 (Agents and actions. Supplements), a journal based in Switzerland.
More context: the Endothelin-1 compound page, all human trials.
Our Notes on the Compound
Endothelin-1: A 21-amino-acid peptide and one of the strongest blood-vessel constrictors in the body; given in research studies of vascular function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.